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ABSTRACT
Objective: This study was designed to determine whether outpatient treatment of pyelonephritis in
pregnancy can reduce costs without compromising safety or efficacy.
Methods: Pregnant patients with uncomplicated initial episodes of acute pyelonephritis were
considered for outpatient management. The outpatient treatment consisted of an initial dose of IV
ceftriaxone (2 g), followed by daily outpatientIM ceftriaxone (2 g) until resolution offever and flank
tenderness, followed by a 10-day course of oral antibiotics. The study group was compared with a
group requiting inpatient treatment and a historical control group meeting the criteria for outpatient
management but having been treated as inpatients in the previous year.
Results: Of the 34 treated as outpatients, only 4 (12%) required hospital admission and 1 devel-
oped an upper urinary tract recurrence. None ofthese patients had premature delivery or any other
serious complication. The historical control group (N 29) included 1 upper urinary tract recur-
rence, no preterm deliveries, and 1 case ofacute respiratory disease syndrome. The outpatient group
required an average of 3.4 daily outpatient visits compared with 3.9 days of hospitalization for the
historical control group. The inpatient group (N 39) was significantly more likely to require
hospitalization >6 days (P- 0.0004), with a trend toward more frequent upper urinary tract
recurrences (6/39 vs. 1/34, P 0.08). The cost analysis revealed a 3-fold difference between outpa-
tient and inpatient therapy ($1,100 vs. $3,350, P < 0.001).
Conclusions: The outpatient treatment of selected patients with pyelonephritis in pregnancy as a
promising approach to reducing costs warrants further investigation. (C) 1995 Wiley-Liss, Inc.
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Acute pyelonephritis complicates 1-2% of all preg-
nancies. It is the most common nonobstetric indica-
tion for antepartum hospitalization. Such patients
are generally treated with IV antibiotics and kept
hospitalized not only until their symptoms have
resolved but 24-48 h beyond complete deferves-
cence. The average hospital stay for this diagnosis
is 3-5 days. The risk of complications of pyelone-
phritis in pregnancy, especially preterm labor and
delivery, as well as the need to prevent recurrences
and permanent renal damage, have dictated this
aggressive approach. The recent emphasis on cost
containment of health care and the shift toward
outpatient management have caused clinicians to
question the necessity of inpatient treatment of such
common problems. Therefore, we designed this
prospective study to determine whether the outpa-
tient treatment of pyelonephritis in pregnancy can
significantly reduce costs without compromising
safety and efficacy.
SUBJECTS AND METHODS
All pregnant patients with a diagnosis of acute
pyelonephritis at the University of California Irv-
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ine Medical Center were considered candidates for
the study. The criteria for the diagnosis of pyelone-
phritis included a temperature >38C, costoverte-
bral angle tenderness (CVAT), and any one of the
following: WBC >11,800 or suggestive symp-
toms, such as dysuria, flank pain, or nausea and
vomiting.
Patients were excluded from outpatient manage-
ment for any of the following reasons: evidence of
sepsis (hypotension, obtundation, pulmonary
edema, disseminated intravascular coagulation),
temperature >39C, severe nausea and vomiting,
uncertain diagnosis, presence of immunocompro-
raise [diabetes mellitus, human immunodeficiency
virus (HIV), IV-drug abuse, or corticosteroid use],
recurrent upper urinary tract infection, concomi-
tant preterm labor, multiple gestation, severe pen-
icillin allergy (not including rash only), history of
renal disease or urinary tract anomalies, or presence
of an indwelling bladder catheter.
Each patient eligible for outpatient treatment
was observed for an initial 2-h period with a base-
line laboratory evaluation (CBC, urinalysis with
culture and sensitivity, and serum BUN and creat-
inine) and IV hydration with of a balanced
crystalloid solution. This study was approved by
the Medical Center’s Institutional Review Board,
and all patients were required to sign informed
consents prior to their inclusion in the study. Once
the diagnosis was confirmed and exclusion criteria
were eliminated, 2 g of IV ceftriaxone (Rocephin (R),
Roche Laboratories, Nutley, NJ) was administered.
This third-generation cephalosporin was chosen for
its long half-life requiring administration only once
every 24 h, its broad-spectrum coverage against
common urinary pathogens, and its documented
efficacy in the outpatient treatment of pyelonephri-
tis and other serious infections in nonpregnant pa-
tients.
2-6 The patient was then seen the following
day in the obstetrical clinic at which time 2 g ofIM
ceftriaxone was administered daily until the resolu-
tion of her fever and CVAT, followed by a 10-day
course of oral antibiotics based on the culture and
sensitivity results. Hospitalization was required for
patients who were considered outpatient failures
based on persistent fever or CVAT beyond 48 h of
parenteral therapy, as well as for patients who de-
veloped nausea and vomiting, were noncompliant
with clinic visits for parenteral antibiotics, showed
evidence of preterm labor, or experienced adverse
drug reactions. However, the requirements for de-
layed hospital admission in this group were not
absolute; if the patient was clearly clinically im-
proved at 48 h, she was continued on outpatient
treatment.
Any patient excluded from outpatient manage-
ment because of the above criteria (referred to as
the inpatient group) received the traditional inpa-
tient therapy consisting of hospitalization and the
administration of parenteral antibiotics until she
became afebrile and her CVAT resolved. This in-
patient treatment was followed by a 10-day course
of oral antibiotics based on urine culture and sensi-
tivities. The admission laboratory evaluation in-
cluded a CBC, catheterized urinalysis with culture
and sensitivities, and serum BUN and creatinine.
Blood cultures were done only on patients with
suspected sepsis. A second antibiotic agent was
added if the patient’s fever persisted beyond 48 h of
parenteral therapy.
The patients were followed prospectively for
treatment failure, other serious complications [adult
respiratory disease syndrome (ARDS), perinephric
abscess, sepsis, or renal insufficiency], upper uri-
nary tract recurrence, or premature delivery. Both
groups (outpatient and inpatient) were compared
with a historical control group which fulfilled the
same criteria for outpatient management, yet had
received traditional inpatient treatment in the year
prior to the study period.
For the purpose of comparing the potential cost
saving of outpatient management, only the hospital
and outpatient costs were calculated. Included in
the total costs for nonhospitalized patients were lab-
oratory fees, emergency room visits for the initial
evaluation, fetal assessment (NST, ultrasound), IV
fluids, follow-up clinic visits, and pharmacy costs.
The costs for hospitalized patients included hospital
room fees, laboratory costs, emergency room and
clinic visits, pharmacy costs, costs of supplies, and
radiology fees. The costs of hospitalization for out-
patent treatment failures were included in the
analysis.
A statistical analysis was performed using the
Mann-Whitney U-test, chi-squared, Fisher’s exact
test, and Student’s t-test where appropriate. The
significance was established using P <0.05. The
sample size was determined based on an 80% chance
of showing a 50% reduction in cost with 95% con-
fidence These calculations determined the need for
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TABLE I. Patient demographics
Historical
Outpatients controls Inpatients
(N=34) (N=29) (N=39)
Age (years)
Gravidity
Parity
EGA
Race (% Hispanic)
Prenatal care (% yes)
Insurance (% MediCal)
23.2 +- 4.9 23.4 +_ 5.9 23 +_ 4.9
3.0 -+ 2.1 2.4 -+ 2.0 2.3 +- 1.5
1.4-+ 1.7 1.2-+ 1.9 0.9-+ 1.4
20.1 +-7 23.1 +-7.1 26.1 +-7.7
85% 93% 77%
35% 38% 62%
50% 41% 72%
aEGA estimated gestational age.
TABLE 2. Clinical characteristics of the outpatient
and historical control groups
Historical
Outpatients controls
(N 34) (N 29)
Initial temperature (C) 37.8 _+ 0.8 37.9 0.8 N.S.
Pulse 102.1 16.3 100.4 _+ 21.4 N.S.
WBC 13.6 4.2 12.3 _+ 3.7 N.S.
Side (% right) 91% 66% 0.01
History of UTI
b (% yes) 26% 28% 0.92
Organism (% E. co/i) 94% 69% 0.009
aN.S.-- not significant.
bUTI Urinary tract infection.
15 patients in each group. The power to demon-
strate that no sacrifice in safety occurred with out-
patient management was calculated retrospectively
after the completion of study.
RESULTS
From March 1, 1992, to March 31, 1993, 73
pregnant patients were diagnosed with acute pyelo-
nephritis. Thirty-four (47%) met the criteria for
outpatient management. Thirty-nine patients (53%)
who were excluded from outpatient management
composed the inpatient group. The reasons for ex-
clusion included fever >39C (15), significant nau-
sea and vomiting (8), diabetes mellitus (5), recur-
rent upper urinary tract infection (5), uncertain
diagnosis (2), and other (4). Twenty-nine controls
(historical control group) were identified from a
computerized data base as described in Subjects and
Methods. All patients in the outpatient group re-
ceived a full course of parenteral antibiotics, al-
though some patients required phone calls to re-
mind them to return for therapy. No patients were
lost to follow-up until after delivery.
Table is a demographic comparison of the 3
groups. There was no significant difference in par-
ity, maternal age, gestational age at diagnosis, race,
or prior prenatal care. The inpatient group was
significantly more likely than the outpatient group
to have government funding (MediCal) (72% vs.
41%, P < 0.01). The majority of patients in all
groups were Hispanic; furthermore, the majority
had received no prior prenatal care.
Table 2 is a comparison of the clinical character-
istics between the outpatient and historical control
groups. There was no difference in initial tempera-
ture, pulse, WBC, or prior urinary tract infection.
The outpatient group was significantly more likely
TABLE 3. Clinical characteristics of the outpatient
and inpatient groups
Outpatients Inpatients
(N 34) (N 29)
Pulse 102. -+ 16.3 105.2 +_ 17.8 N.S.
WBC 13.6 + 4.2 14 _+ 3.9 N.S.
Side (% right) 91% 87% 0.6
History of UTI (% yes) 26% 49% 0.05
Organism (% E. coli) 94% 56% 0.0003
aN.S. not significant.
bUTI Urinary tract infection.
to have right-sided pyelonephritis (91% vs. 66%,
P 0.01) and to have Escherichia coli as the caus-
ative organism (94% vs. 69%, P 0.009). No
cephalosporin-resistant organism was isolated in
either group.
Table 3 is a comparison of the clinical character-
istics between the outpatient and inpatient groups.
There was no significant difference in the initial
WBC or pyelonephritis related to a particular side.
The inpatient group had a higher incidence of prior
urinary tract infection (49% vs. 26%, P 0.05)
and the isolation ofa wider variety ofurinary patho-
gens (56% E. coli vs. 94% E. coli, P 0.0003).
Table 4 depicts the urinary culture isolates of the
3 groups. A comparison of the duration of paren-
teral therapy needed to effect a resolution of the
symptoms and signs of pyelonephritis showed that
the outpatient group required an average of
3.4 -+ 0.6 outpatient visits for evaluation or days
of parenteral antibiotic therapy compared with
3.9 + 2.4 days of hospitalization for the historical
control group and 4.2 + 1.3 days of hospitaliza-
tion for the inpatient group.
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TABLE 4. Urinary isolates
Historical
Outpatients controls Inpatients
N (%) N (%) N (%)
E. coli 32 (94%) 20 (69%) 22 (56%)
Klebsiella pneumoniae 2 (7%) 8 (20%)
K. enterobacteria (3%)
Staphylococcus 1(3%) 2 (5%)
Enterococcus 2 (5%)
Enterobacteria 2 (7%) (3%)
Multiple organisms 3 (10%)
Negative culture 2 (6%) (3%) 3 (8%)
Of the 34 in the outpatient group, 4 required
hospital admission for nausea and vomiting or per-
sistent fever (12% treatment failure rate). None of
these patients required prolonged hospitalization to
effect a resolution of the acute infection (longest
hospital stay was 4 days). One patient in the outpa-
tient group developed a subsequent upper urinary
tract infection with a different organism (Entero-
bacter cloacae) from the original infection (E. coli).
No patients in the outpatient group had serious
complications, other than recurrence. No perterm
deliveries occurred and no cephalosporin-resistant
organisms were isolated in this group. No patients
were lost to follow-up.
Of the 29 historical controls, 4 (14%) required
hospitalization >6 days. One patient developed an
upper urinary tract recurrence. One patient devel-
oped ARDS on the second hospital day. This com-
plication was felt to be iatrogenic because ofvolume
overload. The patient responded to fluid restriction
and supplemental oxygen, and assisted ventilation
was not required. No preterm deliveries occurred,
and no cephalosporin-resistant organisms were iso-
lated.
Ofthe 39 patients excluded from outpatient man-
agement in the inpatient group, 8 (21%) required
prolonged hospitalization >6 days to effect a cure.
Six (15%) experienced an upper urinary tract re-
currence. Two patients (6%) had other serious com-
plications (1 had a perinephric abscess, and the
other had transient renal insufficiency). Three pa-
tients (7%) had cephalosporin-resistant organisms
(2 enterococcal infections and methicillin-resis-
tant staphylococcal infection). No preterm deliver-
ies occurred in the inpatient group. Compared with
the outpatient group, these hospital patients were
significantly more likely to require prolonged ther-
apy >6 days (P 0.0004), with a trend toward
more frequent upper urinary tract recurrences
(p
A cost analysis demonstrated a 3-fold difference
between outpatient and inpatient therapy ($1,100
vs. $3,350, P <0.001). When all therapy for the
episode of pyelonephritis was included, the outpa-
tient group cost was $1,100 --+ $1,105; the histori-
cal control group cost was $3,350 + $2,150; and
the inpatient group cost was $3,500 -+ $1,235. The
hospital charges (as opposed to costs) were not cal-
culated, but the difference in the groups would be
even more dramatic if these charges had been com-
pared.
A retrospective analysis of the power to deter-
mine the safety of outpatient therapy showed that,
with the sample size in this study, we achieved a
65% chance of showing a 2-fold increase in any
serious complication with 95% confidence, and no
increases in such complications were seen.
DISCUSSION
Physicians and hospitals are being subjected to in-
creasing pressures to reduce the cost of health care.
One of the prime determinants of overall cost,
especially of acute problems, is the need for and
duration of hospitalization. In the past, only opti-
mal health care, without much regard for cost,
determined the need for hospitalization. In the case
of pyelonephritis in pregnancy, with an apprecia-
tion of the major associated complications, particu-
larly preterm labor and delivery, inpatient therapy
with IV antibiotics and aggressive hydration be-
came the standard of care. Recently, reports have
appeared suggesting that patients with other serious
acute infections, such as streptococcal endocarditis,
childhood meningitis, and pyelonephritis in non-
pregnant patients, can be safely and effectively
treated as outpatients, especially with the availabil-
ity of long-acting broad-spectrum antibiotics, z-6
No previous reports have tested the possibility of
similarly treated pyelonephritis in pregnancy al-
though a recent study reported efficacy with oral
antibiotics used in the inpatient setting.
7
This first such study, although limited by the
relatively small sample sizes, demonstrates that out-
patient management of pyelonephritis in pregnancy
substantially reduces the cost of treating this rela-
tively common problem. Nearly 90% of the pa-
tients who met the inclusion criteria were success-
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fully treated as outpatients with no serious
complications, no preterm deliveries, and only
patient (3%) developing a recurrent urinary tract
infection. These results were as good as or better
than those seen with a reasonably similar historical
control group previously treated as inpatients, who
otherwise would have been eligible by these criteria
for outpatient management.
With our conservative protocol, we were still
able to treat nearly half of all patients presenting
with pyelonephritis at an average cost savings of
more than $2,200/patient. The savings would be
even greater in the private setting in which many of
these patients would have their initial evaluation
and treatment in the physician’s office.
One might question the criteria we chose to de-
fine pyelonephritis, specifically allowing the inclu-
sion of patients with negative cultures. Since cul-
tures are not available at the time the diagnosis must
be made and few clinicians use urine Gram stains,
we felt that it would not be appropriate to eliminate
these patients, since they had prospectively con-
sented and had been included in the study protocol.
Similarly, we allowed the inclusion of all patients
with identical criteria in the 2 control groups. How-
ever, eliminating the few patients with negative
cultures would not have changed the results or con-
clusions of this study.
The primary limitation of this study is our in-
ability to make more definitive statements about the
safety of outpatient therapy because of the relatively
small sample size studied. Therefore, this study
must be viewed as a preliminary report suggesting
promising results and requiring corroboration by
subsequent larger randomized studies to establish
outpatient therapy as a safe alternative. The pur-
pose of a retrospective power analysis is not to give
scientific credibility to the sample size but to give
the reader an impression of the magnitude of dif-
ference in complications that a study of this sample
size might be able to demonstrate. Although large
differences in the rates of any serious complications
expected to be seen in this study were not, larger
studies are needed to determine if any compromise
in patient safety results from such a treatment pro-
tocol. It is important to emphasize that hospitaliza-
tion itself is not necessarily the safest alternative. In
a previous report, we discovered a surprisingly
high rate (8%) of pulmonary edema and ARDS in
hospitalized patients with acute pyelonephritis in
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pregnancy.
8 A multifactorial analysis determined
that excess IV fluid administration and parenteral
tocolytic use iatrogenically contributed to this seri-
ous complication. A similar complication seen in
this study occurred in a patient from the historical
control group who appeared to have received exces-
sive hydration. Nonetheless, it is important that we
scrutinize the safety and efficacy of such outpatient
protocols in a carefully controlled setting before
these protocols are imposed on us by third-party
payers.
Because of this concern, we used relatively strin-
gent and conservative exclusion criteria. These ex-
clusion criteria, especially fever >39C and severe
nausea and vomiting, were the reason that the out-
patient treatment could be applied to fewer than
half of the patients presenting with this diagnosis.
Home health nursing, including outpatient IV ther-
apy, may make it possible to extend such treatment
to the excluded patients as well. However, the re-
sults of this study indicate that the exclusions were
appropriately chosen, as both the serious complica-
tions and the vast majority of prolonged hospital-
izations and recurrences occurred in the inpatient
group, which met the exclusion criteria.
The availability of newer, long-acting, safe anti-
biotics with a broad-spectrum of activity against
pathogens found in urinary tract infections makes
this type of study feasible. Ceftriaxone is such an
antibiotic. It is a broad-sprectrum, third-genera-
tion cephalosporin that when administered IM is
completely absorbed, reaching peak plasma con-
centrations in 2-3 h, and eliminated in a half-life of
6-9 h. Two-thirds of this drug is excreted in the
urine, and urinary concentrations of 40% of the
peak concentrations are maintained for 24 h. It has
an excellent spectrum of activity against commonly
occurring gram-negative and gram-positive uri-
nary pathogens.
9 Although the experience of ceph-
alosporins in pregnancy has generally demonstrated
safety, this relatively new cephalosporin is listed as
a "Pregn,ancy Category B" with no evidence of
harm in high-dose animal studies and limited expe-
rience in human pregnancies.
10 Safety in neonates,
however, has been established.
Optimally, all cases of pyelonephtitis should be
prevented by early prenatal care with screening and
treatment of asymptomatic bacteriuria. As seen in
this study, the vast majority of our patients pre-
sented with pyelonephritis prior to their first pre-
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natal visit. Surprisingly, we were able to convince
all patients to follow the protocol and keep their
appointments once the diagnosis had been made.
Nonetheless, many patients do not seek prenatal
care early enough, if at all. Even under good pre-
natal care, patients all too often develop acute upper
urinary tract infections. Even screening all patients
at the first prenatal care visit will not eliminate all
such cases. Gilstrap et al.
lz have shown that as
many as one-third of all significant bacteriurias will
occur later in pregnancy in women with initially
negative cultures and about 25% or more of these
will develop pyelonephritis if the condition goes
undetected and untreated. Therefore, selective cost-
savings protocols are needed to deal with this com-
mon antepartum diagnosis that adds substantially to
the cost of maternity and newborn care.
This preliminary study does demonstrate that a
selective approach to outpatient management of
acute pyelonephritis in pregnancy can substantially
reduce the cost of treating this entity without appar-
ently compromising patient safety. Larger studies
are needed to document the safety of such an outpa-
tient management scheme before such an approach
is accepted and applied.
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